5-carboxymethyl-2-hydroxymuconate Delta-isomerase

SAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference

Retrieved on: 
Thursday, November 3, 2022

SABs Chief Operating Officer Christoph Bausch, Ph.D., led two presentations at the conference on Tuesday, Nov. 1.

Key Points: 
  • SABs Chief Operating Officer Christoph Bausch, Ph.D., led two presentations at the conference on Tuesday, Nov. 1.
  • Tc Bovine, SABs genetically engineered cows, mount the same immune response as humans, only with a much higher concentration of targeted neutralizing antibodies.
  • Data from the in vitro neutralizing capacity of SAB-185 was tested against 10 variant SARS-CoV-2 strains, including several Omicron variants.
  • Our versatile DiversitAb platform is applicable to a wide range of serious unmet needs in human diseases.

SAB Biotherapeutics Unveils New Data at ISIRV OPTIONS XI Conference Validating SAB-176 Proof of Concept in Reducing Viral Load and Improving Symptoms of Influenza and Showing SAB-185 Effective Against Multiple COVID-19 Variants Including Omicron

Retrieved on: 
Wednesday, September 28, 2022

Participants received 25 mg/kg of SAB-176 diluted in normal saline or an equivalent volume of normal saline (placebo) in a single IV infusion.

Key Points: 
  • Participants received 25 mg/kg of SAB-176 diluted in normal saline or an equivalent volume of normal saline (placebo) in a single IV infusion.
  • SABs challenge trial for SAB-176 established proof of concept for this important clinical program, said Alexandra Kropotova, M.D., Chief Medical Officer at SAB.
  • The in vitro neutralizing capacity of SAB-185 was tested against 10 variant SARS-CoV-2 strains, including several Omicron variants.
  • This data suggests that SAB-185 may be an effective immunotherapy even in the presence of ongoing viral mutation, Dr. Kropotova said.

Recbio Provides Updates on First Lyophilized mRNA Vaccine and Pre-clinical Data Showing Long-term stability and Strong immunogenicity against SARS-CoV-2

Retrieved on: 
Tuesday, February 15, 2022

The lyophilized mRNA-LNP nanoparticle vaccine is delivered by an LNP delivery system and achieved stability at 4and 25based on a self-developed lyophilization technology.

Key Points: 
  • The lyophilized mRNA-LNP nanoparticle vaccine is delivered by an LNP delivery system and achieved stability at 4and 25based on a self-developed lyophilization technology.
  • The vaccine can be stored and transported in conventional cold chain conditions, greatly improving the accessibility of mRNA vaccine.
  • Notably, the Delta-specific mRNA vaccine can induce a high-level neutralization response in mice against both the wild-type and the current global pandemic strain Omicron.
  • Recbio has a high-value vaccine portfolio consisting of HPV vaccine candidates, COVID-19 vaccine candidates, shingles vaccine candidates, influenza vaccine candidates, adult TB vaccine candidates, etc.

IGM Biosciences Advances Novel Antibody IGM-6268 Into Clinical Trials for the Treatment and Prevention of COVID-19

Retrieved on: 
Wednesday, February 9, 2022

MOUNTAIN VIEW, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its progress in two Phase 1 clinical trials evaluating IGM-6268, an anti-SARS-CoV-2 IgM monoclonal antibody, for the treatment and prevention of COVID-19. The first, a Phase 1 clinical trial in the U.S., is a multi-center, randomized, double-blinded, placebo-controlled single (SAD) and multiple (MAD) ascending dose study to assess the safety, tolerability, and pharmacokinetics of IGM-6268 administered intranasally in healthy volunteers. The first two dose cohorts of healthy volunteers have been successfully cleared in the U.S., and data from the study are expected in the first half of 2022. The second, a Phase 1a/1b clinical trial in South Africa, is a multi-center, randomized, double-blinded, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of IGM-6268 administered intranasally first in healthy volunteers, once an appropriate dose cohort has been cleared, in outpatients with mild to moderate COVID-19. The first dose cohort of healthy volunteers has been cleared in the South Africa study, and data from the study are expected in mid-2022.

Key Points: 
  • IGM-6268 is an engineered IgM antibody that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike protein.
  • Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies.
  • Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies.
  • Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Sunshine Biopharma Expands Board of Directors

Retrieved on: 
Wednesday, November 3, 2021

MONTREAL, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has expanded its board of directors from three to five and has appointed three new, independent directors.

Key Points: 
  • MONTREAL, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has expanded its board of directors from three to five and has appointed three new, independent directors.
  • We welcome them on board and look forward to calling on their expertise in our ongoing efforts to take the Company to new heights, said Dr. Steve Slilaty, CEO of Sunshine Biopharma.
  • Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4.
  • In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound.

Sunshine Biopharma Files a Patent Application Covering mRNA Molecules for Treatment of Neurodegenerative Diseases

Retrieved on: 
Wednesday, October 6, 2021

Sunshine Biopharmas patent application contains experimental results showing that certain mRNA molecules provide protective effects against oxidative stress in differentiated neuronal cells, a process that mimics neuronal degeneration.

Key Points: 
  • Sunshine Biopharmas patent application contains experimental results showing that certain mRNA molecules provide protective effects against oxidative stress in differentiated neuronal cells, a process that mimics neuronal degeneration.
  • Neurodegenerative diseases include amyotrophic lateral sclerosis (ALS), Parkinson's disease, multiple sclerosis, Alzheimer's disease, and Huntington's disease.
  • These similarities suggest that a given therapeutic approach for one neurodegenerative disease might ameliorate other diseases in the class.
  • In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound.

Neoleukin Therapeutics Announces Oral Presentation at IDWeek 2021 of Data Demonstrating that NL-CVX1, a Computationally Designed De Novo Protein, Can Block Infection by SARS-CoV-2 Viral Variants of Concern

Retrieved on: 
Wednesday, September 29, 2021

SEATTLE, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced new data highlighting the ability of its de novo protein decoy, NL-CVX1, to block SARS-CoV-2 infection in certain viral variants. Data were presented in an oral presentation at IDWeek 2021 titled “Antiviral NL-CVX1 efficiently blocks infection by SARS-CoV-2 viral variants of concern (VOC)” (Conference Track A1, Session [O-27]: Novel Microbial Agents).*

Key Points: 
  • Data were presented in an oral presentation at IDWeek 2021 titled Antiviral NL-CVX1 efficiently blocks infection by SARS-CoV-2 viral variants of concern (VOC) (Conference Track A1, Session [O-27]: Novel Microbial Agents).
  • *
    NL-CVX1 is a computationally designed, de novo protein that acts as a hACE2 decoy, neutralizing SARS-CoV-2 both in vitro and in vivo and inhibiting SARS-CoV-2 replication.
  • We are grateful to our outstanding collaborators, including Dr. Maria Rebelo, presenter of these exciting data at IDWeek 2021.
  • NL-CVX1 is a computationally designed, de novo protein that binds to the spike protein of SARS-CoV-2.

Study Confirms Viraleze Antiviral Nasal Spray Provides Protection Against SARS-CoV-2 in Challenge Model

Retrieved on: 
Monday, August 23, 2021

The antiviral agent in Viraleze, SPL7013, has previously been shown in vitro to have potent antiviral and virucidal activity in multiple variants of SARS-CoV-2, including inactivation of >99.9% of the Delta variant.

Key Points: 
  • The antiviral agent in Viraleze, SPL7013, has previously been shown in vitro to have potent antiviral and virucidal activity in multiple variants of SARS-CoV-2, including inactivation of >99.9% of the Delta variant.
  • Viraleze was developed for application in the nasal cavity to help reduce exposure to respiratory viruses, including SARS-CoV-2.
  • The latest study, conducted at The Scripps Research Institute, used a humanised SARS-CoV-2 mouse model recommended by the WHO.
  • Starpharma CEO, Dr Jackie Fairley, said: "In this study Viraleze was highly protective against SARS-CoV-2 challenge in an established SARS-CoV-2 animal model of coronavirus infection.

Study Confirms Viraleze Antiviral Nasal Spray Provides Protection Against SARS-CoV-2 in Challenge Model

Retrieved on: 
Monday, August 23, 2021

The antiviral agent in Viraleze, SPL7013, has previously been shown in vitro to have potent antiviral and virucidal activity in multiple variants of SARS-CoV-2, including inactivation of >99.9% of the Delta variant.

Key Points: 
  • The antiviral agent in Viraleze, SPL7013, has previously been shown in vitro to have potent antiviral and virucidal activity in multiple variants of SARS-CoV-2, including inactivation of >99.9% of the Delta variant.
  • Viraleze was developed for application in the nasal cavity to help reduce exposure to respiratory viruses, including SARS-CoV-2.
  • The latest study, conducted at The Scripps Research Institute, used a humanised SARS-CoV-2 mouse model recommended by the WHO.
  • Starpharma CEO, Dr Jackie Fairley, said: "In this study Viraleze was highly protective against SARS-CoV-2 challenge in an established SARS-CoV-2 animal model of coronavirus infection.

Sunshine Biopharma’s Coronavirus Treatment Anticipated to be Effective Against Delta and the Other Variants of Concern

Retrieved on: 
Thursday, August 12, 2021

These finding indicate that our PLpro inhibitors currently under development at the University of Georgia would likely be effective against all of the VOC.

Key Points: 
  • These finding indicate that our PLpro inhibitors currently under development at the University of Georgia would likely be effective against all of the VOC.
  • The VOC currently recognized by theWorld Health Organization and theCDCin the United States include the Alpha, Beta, Gamma and Delta variants.
  • All of the mutations of these variants were found to occur outside of the PLpro catalytic domain where our inhibitors function.
  • Mutations falling outside of the catalytic domain of an enzyme are generally considered to be inconsequential to the activity of that enzyme.